Search

Your search keyword '"Lange, Joep"' showing total 1,247 results
Start Over Author "Lange, Joep"
1,247 results on '"Lange, Joep"'

1. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study

Author

Osibogun, Akin, Wallis, Carole L., Nalubwama, Cathy, Letsoalo, Esrom, Senono, Fred, Adelabu, Hameed, Kakooza, Hanipha, Namata, Harriet, Sanne, Ian, Nankya, Immaculate, Menke, Jack, Lange, Joep M.A., Sigaloff, Kim C.E., Mandaliya, Kishor, Hardman, Margaret, Siwale, Margaret, de Jager, Marleen, Dolan, Marian, Botes, Mariette E., O'Mello, Martin, Wellington, Maureen, Mutebi, Miiro, Nakitto, Miriam, Labib, Moheb, Pakker, Nadine, Ondoa, Pascale, Mugyenyi, Peter, Ive, Prudence, Nakanjako, Ritah, Schuurman, Rob, Lüthy, Ruedi, Balinda, Sheila N., Akanmu, Sulaimon, Boender, T. Sonia, Adeyemo, Titilope A., Rodoye, Tope, Stevens, Wendy S., Namala, Winnie, Inzaule, Seth C, Hamers, Raph L, Noguera-Julian, Marc, Casadellà, Maria, Parera, Mariona, Kityo, Cissy, Steegen, Kim, Naniche, Denise, Clotet, Bonaventura, Rinke de Wit, Tobias F, and Paredes, Roger

Published
2018
Full Text
View/download PDF

2. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria.

Author

Nosyk, Bohdan, Audoin, Bertrand, Beyrer, Chris, Cahn, Pedro, Granich, Reuben, Havlir, Diane, Katabira, Elly, Lange, Joep, Lima, Viviane D, Patterson, Thomas, Strathdee, Steffanie A, Williams, Brian, and Montaner, Julio

Subjects
Humans, HIV Infections, Treatment Outcome, Antiretroviral Therapy, Highly Active, Viral Load, Sentinel Surveillance, Incidence, Virus Replication, Research Design, Cost-Benefit Analysis, Female, Male, Randomized Controlled Trials as Topic, Prevention, Substance Misuse, Clinical Research, Clinical Trials and Supportive Activities, HIV/AIDS, Infection, Good Health and Well Being, Bradford Hill criteria, causality, HAART, HIV prevention, human immunodeficiency virus, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology
Abstract

In recent years, evidence has accumulated regarding the ability of HAART to prevent HIV transmission. Early supportive evidence was derived from observational, ecological and population-based studies. More recently, a randomized clinical trial showed that immediate use of HAART led to a 96% decrease in HIV transmission events within HIV serodiscordant heterosexual couples. However, the generalizability of the effect of HAART, and the population-level impact on HIV transmission continues to generate substantial debate. We, therefore, conducted a review of the evidence regarding the preventive effect of HAART on HIV transmission within the context of the Bradford Hill criteria for causality. Taken together, we find the accumulated evidence supporting HIV treatment as prevention meets each of the Bradford Hill criteria for causality. We conclude that the opportunity cost of inaction while waiting for additional evidence on the generalizability of effect in other risk groups is too high. Efforts should be redoubled to mobilize the financial capital and political will to optimize implementation of HIV Treatment as Prevention strategies on a wide scale.

Published
2013

9. Whither or Wither Microbicides?

Author

Grant, Robert M., Hamer, Dean, Hope, Thomas, Johnston, Rowena, Lange, Joep, Lederman, Michael M., Lieberman, Judy, Miller, Christopher J., Moore, John P., Mosier, Donald E., Richman, Douglas D., Schooley, Robert T., Springer, Marty S., Veazey, Ronald S., and Wainberg, Mark A.

Published
2008

16. GB Virus C Infection and Survival in the Amsterdam Cohort Study

Author

Stapleton, Jack T., Chaloner, Kathryn, Williams, Carolyn F., Van der Bij, Akke K., Kloosterboer, Nico, Prins, Maria, Boeser-Nunnink, Brigitte, Geskus, Ronald B., Lange, Joep M. A., Coutinho, Roel A., and Schuitemaker, Hanneke

Published
2005

32. Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared with Zidovudine Monotherapy

Author

Wellcome Resistance Study Collaborative Group, Schooley, Robert T., Ramirez-Ronda, Carlos, Lange, Joep M. A., Cooper, David A., Lavelle, James, Lefkowitz, Lewis, Moore, Mark, Larder, Brendan A., St. Clair, Marty, Mulder, Jan Willem, McKinnis, Ray, Pennington, Kevin N., Harrigan, P. Richard, Kinghorn, Ian, Steel, Helen, and Rooney, James F.

Published
1996

33. Advanced liver fibrosis by transient elastography, Fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: Role of vitamin D levels

Author

Avihingsanon, Anchalee, Jitmitraparp, Salyavit, Tangkijvanich, Pisit, Ramautarsing, Reshmie A., Apornpong, Tanakorn, Jirajariyavej, Supunee, Putcharoen, Opass, Treeprasertsuk, Sombat, Akkarathamrongsin, Srunthron, Poovorawan, Yong, Matthews, Gail V, Lange, Joep MA, and Ruxrungtham, Kiat

Published
2014
Full Text
View/download PDF

35. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic

Author

Cohen, Myron S., Hellmann, Nick, Levy, Jay A., DeCock, Kevin, and Lange, Joep

Subjects
Company distribution practices, HIV infection -- Drug therapy, HIV infection -- Prevention, HIV infection -- Statistics, HIV infection -- Distribution, Epidemics -- United States, Epidemics -- Prevention
Abstract

The most up-to-date estimates demonstrate very heterogeneous spread of HIV-1, and more than 30 million people are now living with HIV-1 infection, most of them in sub-Saharan Africa. The efficiency of transmission of HIV-1 depends primarily on the concentration of the virus in the infectious host. Although treatment with antiviral agents has proven a very effective way to improve the health and survival of infected individuals, as we discuss here, the epidemic will continue to grow unless greatly improved prevention strategies can be developed and implemented. No prophylactic vaccine is on the horizon. However, several behavioral and structural strategies have made a difference--male circumcision provides substantial protection from sexually transmitted diseases, including HIV-1, and the application of antiretroviral agents for prevention holds great promise., Introduction Now, 28 years after AIDS was first recognized (1), HIV-1 requires continued global focus and investment. The cumulative total of individuals infected with HIV-1 and deaths due to AIDS [...]

Published
2008

37. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals

Author

Reynes, Jacques, Arasteh, Keikawus, Clotet, Bonaventura, Cohen, Calvin, Cooper, David A., Delfraissy, Jean-Francois, Eron, Joseph J., Jr., Henry, Keith, Katlama, Christine, Kuritzkes, Daniel R., Lalezari, Jacob P., Lange, Joep, Lazzarin, Adriano, Montaner, Julio S.G., Nelson, Mark, O'Hearn, Mary, Stellbrink, Hans-Jurgen, Trottier, Benoit, Walmsley, Sharon L., Buss, Neil E., DeMasi, Ralph, Chung, Jain, Donatacci, Lucille, Guimaraes, Denise, Rowell, Lucy, Valentine, Adeline, Wilkinson, Martin, and Salgo, Miklos P.

Subjects
Enfuvirtide -- Health aspects, Enfuvirtide -- Research, Anti-HIV agents -- Health aspects, Anti-HIV agents -- Research, Antiviral agents -- Health aspects, Antiviral agents -- Research, HIV patients -- Care and treatment, HIV patients -- Research, Health
Abstract

The additional 48-week optional treatment extension of the T-20 versus Optimized Regimen Only (TORO) studies evaluated long-term safety and efficacy of enfuvirtide (ENF) through week 96 in patients receiving ENF plus optimized background (OB) and patients switching to ENF plus OB from OB alone. Patient randomization was 2:1 to ENF plus OB (n = 663) and OB (n = 334), of which 89.7% and 89.8% were male, 89.3% and 88.6% were Caucasian, and median age was 41 and 42 years, respectively. HIV risk factors were comparable between the ENF plus OB and OB groups with the major factors being 65.2% versus 66.2% homosexual contact, 17.8% versus 19.8% heterosexual contact, 4.1% versus 4.8% bisexual contact, respectively, and 6.9% injection drug use in both groups. OB patients were allowed to switch to ENF plus OB at virologic failure before week 48 and required to switch at week 48 to continue in the study (n = 230). Efficacy and safety assessments were conducted for each group. At week 96, 55% of ENF plus OB subjects completed the study and 26.5% achieved a viral load of less than 400 copies per milliliter (17.5% achieved less than 50 copies per milliliter). Viral load and CD4 mean change from baseline was -2.1 and -1.1 [log.sub.10] HIV-1-RNA copies per milliliter and +166 and +116 CD4 cells/[mm.sup.3] for ENF plus OB and switch patients, respectively. No new ENF-related safety issues emerged in weeks 48-96. Injection site reactions led to discontinuation in 7% and 10% of ENF plus OB and switch patients, respectively. In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial.

Published
2007

38. CD4 cell counts of 800 cells/m[m.sup.3] or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/m[m.sup.3] or greater

Author

Gras, Luuk, Kesselring, Anouk M., Griffin, James T., Sighem. Ard I. van, Fraser, Christophe, Ghani, Azra C., Miedema, Frank, Reiss, Peter, Lange,Joep M.A., and de Wolf, Frank

Subjects
Highly active antiretroviral therapy -- Health aspects, CD4 lymphocytes -- Research, HIV infection -- Drug therapy, Health
Abstract

The CD4 cell count changes are investigated in therapy-naive patients during 7 years of highly active antiretroviral therapy (HAART) in an observational cohort. It is concluded that restoration to CD4 cell counts mare than or equal to 800 cells/m[m.sup.3] is feasible within 7 years of HAART in most HIV patients.

Published
2007

39. Effects of active treatment discontinuation in patients with a [CD4.sup.+] T-cell nadir greater than 350 cells/[mm.sup.3]

Author

Pogany, Katalin, Vanvalkengoed, Irene G., Prins, Jan M., Nieuwkerk, Pythia T., van der Ende, Ineke, Kauffmann, Robbert H., Kroon, Frank P., Verbon, Annelies, Nievaard, Marianne F., Lange, Joep M.A., and Brinkman, Kees

Subjects
Highly active antiretroviral therapy -- Health aspects, Highly active antiretroviral therapy -- Risk factors, HIV patients -- Health aspects, Health
Abstract

The safety and efficacy of discontinuing highly active antiretroviral therapy (HAART) in HIV-1-positive patients who initiated HAART at a [CD4.sup.+] T-cell count greater than 350 cells/[mm.sup.3] are evaluated. The results have shown that there is no improvement found in the quality of life, though HAART can safely be interrupted in patients with a high CD4 T-cell nadir.

Published
2007

40. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings

Author

Sow, Papa S., Otieno, Leander F., Bissagnene, Emmanuel, Kityo, Cissy, Bennink, Ruurd, Clevenbergh, Philippe, Wit, Ferdinand W.N.M., Waalberg, Esther, Rinke de Wit, Tobias, and Lange, Joep M.

Subjects
HIV patients -- Medical examination, HIV patients -- Care and treatment, Antiviral agents -- Dosage and administration, Antiviral agents -- Complications and side effects, HIV infection -- Diagnosis, Health
Abstract

The final results of the Cohort Program to Evaluate Access to Antiretroviral Therapy and Education (CARE) initiative are described. The virologic and immunologic responses to highly active antiretroviral therapy in resource-limited African settings could be as good as in Western settings if adequate medical care, counseling, proper instruction, and education of patients and medical staff during the entire study is warranted with special care in the early phase.

Published
2007

41. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens

Author

Kerr, Stephen J., Duncombe, Chris, Avihingsanon, Anchalee, Ananworanich, Jintanat, Boyd, Mark, Sopa, Bunruan, Medtech, B., Chuenyam, Theshinee, Cooper, David A., Lange, Joep M.A., Phanuphak, Praphan, and Ruxrungtham, Kiat

Subjects
Protease inhibitors -- Health aspects, Antiviral agents -- Health aspects, Asians -- Health aspects, HIV infection -- Care and treatment, Health, Care and treatment, Health aspects
Abstract

There are limited data about dyslipidemia in Asian patients treated with combination antiretroviral therapy. To assess the relative association of different protease-inhibitor-containing regimens with the degree of dyslipidemia, fasting lipid [...]

Published
2007

42. HAART for the HIV-infected employees of large companies in Africa

Author

Van der Borght, Stefaan, de Wit, Tobias F. Rinke, Janssens, Vincent, van der Loeff, Maarten F. Schim, Rijckborst, Henk, and Lange, Joep M.A.

Subjects
Antiviral agents -- Dosage and administration, Antiviral agents -- Finance, Employee benefits -- Finance, HIV patients -- Finance, HIV patients -- Drug therapy, Prescription drug plans -- Finance, Developing countries -- Health aspects, Employee benefits, Company financing
Published
2006

44. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

Author

Troittier, Benoit, Walmsley, Sharon, Reynes, Jacues, Piliero, Peter, O'Hearn, Mary, Nelson, Mark, Montaner, Julio, Lazzarin, Adriano, Lalezari, Jacob, Katlama, Christine, Henry, Keith, Cooper, David, Clotet, Bonaventura, Arasteh, Keikawus, Delfraissy, Jean-Francois, Stellbrink, Hans-Jurgen, Lange, Joep, Kuritzkes, Daniel, Eron, Joseph J., Jr., Cohen, Calvin, Kinchelow, Tosca, Bertasso, Anne, Labriola-Tompkins, Emily, Shikhman, Anna, Atkins, Belinda, Bourdeau, Laurence, Natale, Christopher, Hughes, Fiona, Jain Chung, Guimaraes, Denise, Drobnes, Claude, Bader-Weder, Silvia, DeMasi, Ralph, Smiley, Lynn, and Salgo, Miklos P.

Subjects
Antiviral agents -- Research, HIV infection -- Care and treatment, Drug therapy, Combination, Health
Abstract

The analysis of pooled safety data from the pivotal phase three T-20 Versus Optimized Background Regimen Only (TORO) trials indicates that enfuvirtide is a well-tolerated antiretroviral agent with a maintained safety profile over 48 weeks in treatment-experienced HIV-1-infected adults. It is found that the rates of other adverse agents favored enfuvirtide or were generally comparable between treatments.

Published
2005

45. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen into 1 and 2 clinical trials

Author

Nelson, Mark, Arasteh, Keikawus, Clotet, Bonaventura, Cooper, David A., Henry, Keith, Katlama, Christine, Lalezari, Jacob P., Lazzarin, Adriano, Montaner, Julio S.G., O'Hearn, Mary, Piliero, Peter J., Reynes, Jacques, Cohen, Calvin, Eron, Joseph J., Jr., Kuritzkes, Daniel R., Lange, Joep, Stellbrink, Hans-Jurgen, Delfraissy, Jean-Francois, Buss, Neil E., Donatacci, Lucille, Wat, Cynthia, Gulmaraes, Denise, Demasi, Ralph, Jain Chung, and Salgo, Miklos P.

Subjects
Antiviral agents -- Research, Antiviral agents -- Licensing, certification and accreditation, HIV infection -- Drug therapy, Health
Abstract

Exploratory analyses to compare treatment effects between the enfuvirtide and control groups by different factors after 48 weeks that were carried out are discussed. It was demonstrated that the efficacy to enfuvirtide is durable plus optimized background over 48 weeks.

Published
2005

46. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy

Author

Leth, Frank van, Huisamen, Casper B., Wit, Ferdinand W. N. M., Badaro, Roberto, Lange, Joep M. A., Hall, David B., Vandercam, Bernard, Wet, Joss de, and Montaner, Julio S. G.

Subjects
Nevirapine -- Research, RNA -- Research, Health, Efavirenz (Medication) -- Research
Abstract

An interim analysis based on the data from the first 400 patients to assess possible differences in plasma HIV-1RNA (pVL) decline between the treatment groups is presented. A similar rate of initial decline of pVL for nevirapine (NVP), efavirenz (EFV), and NVP + EFV after adjusting for baseline pVL and region is shown.

Published
2005

47. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment

Author

Nuesch, Reto, Ananworanich, Jintanat, Sirivichayakul, Sunee, Ubolyam, Sasiwimol, Siangphoe, Umaporn, Hill, Andrew, Cooper, David, Lange, Joep, Phanuphak, Praphan, and Ruxrungtham, Kiat

Subjects
HIV infection -- Drug therapy, Drug resistance -- Research, Antiviral agents -- Dosage and administration, Health, Health care industry
Published
2005

48. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection

Author

Cardiello, Peter G., Hassink, Elly, Ananworanich, Jintanat, Srasuebkul, Preeyaporn, Samor, Tarika, Mahanontharit, Apicha, Ruxrungtham, Kiat, Hirschel, Bernard, Lange, Joep, Phanuphak, Praphan, and Cooper, David A.

Subjects
HIV infection -- Risk factors, HIV infection -- Diagnosis, HIV infection -- Care and treatment, Antiviral agents -- Dosage and administration, Health, Health care industry
Published
2005

49. Preface

Author

Volberding, Paul, primary, Greene, Warner, additional, Lange, Joep, additional, Gallant, Joel, additional, and Sewankambo, Nelson, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results